PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial

This study was funded by a 2017 Prostate Cancer Foundation Challenge Award (S.J.P. and S.J.F.) and an NCI SPORE Award (P50CA092131). Studies reported in this publication were also supported by the Doug and Rhonda Collier Foundation Fund, the Fiterman Family Foundation Fund and the Borstein Foundation Fund. Work performed in the GMP facility and the COH Pathology Core was supported by the National Cancer Institute of the National Institutes of Health under grant no. P30CA033572. We thank staff at the Analytical Pharmacology Core Facility for their assistance in performing correlatives assays and the T Cell Therapeutics Research Laboratories and the Center for Biomedicine and Genetics for CAR T cell manufacturing and product release. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes.

All required clinical data have been uploaded to ClinicalTrials.gov. All requests for raw and analyzed data and materials should be addressed to the corresponding authors and will be reviewed by the institution to verify whether the request is subject to any intellectual property or confidentiality obligations. Patient data may be subject to patient confidentiality. Any data and materials that can be shared will be released via a material transfer agreement. Source data are provided with this paper.

Extended Data Fig. 1 PSCA-CAR T cell product characterization.

A description of the methods and the code used to process and analyze the scRNA-seq and TCR-seq data is available at https://github.com/pachterlab/DBALLSMRDMCMGWSTPMBDKPFP_2023. The TCR and single-cell RNA-seq data can be accessed at https://www.dropbox.com/scl/fo/rhgr2y28az1e2h0avaj0l/h?rlkey=6a4wlnus0png19mb80g42uja1&dl=0 (using password ‘coh_128781’).

T.B.D. is a consultant for AstraZeneca and Janssen. S.J.P. and S.J.F. are scientific advisors to and receive royalties from Mustang Bio. S.J.P. is also a scientific advisor and/or receives royalties from Imugene, Adicet Bio, Port Therapeutics and Celularity. S.J.P. and S.J.F. are listed as co-inventors on a patent on chimeric antigen receptors targeted to PSCA, which is owned by the City of Hope. The other authors declare no competing interests.